medac GmbH
Nadja Hamann has a diverse work experience spanning multiple industries. Nadja currently holds the position of Head of Portfolio & Business Development Global Business Generics at medac GmbH, a role they have held since January 2023. Prior to this, they worked at the same company as the Manager Portfolio & Business Development | Global Business Generics from April 2019 to January 2023. In addition, they were an In-Licensing Manager at medac GmbH from April 2018 to March 2019. Before joining medac GmbH, Nadja worked at Welding GmbH & Co. KG as a Project Manager Portfolio & Business Development from November 2013 to March 2018. Nadja also has experience in the pharmaceutical industry, having worked as Generic Supply at Alfred E. Tiefenbacher (GmbH & Co. KG) from September 2009 to October 2013. Prior to that, they worked as the Verlagsleitung at Helmut Metz Verlag from September 2006 to August 2009, and as a Disponentin at Topteq Tankstellentechnik GmbH from March 2005 to August 2006.
Nadja Hamann obtained their Bachelor of Arts degree in Betriebswirtschaft, with a focus on Medienmanagement, from the Hamburg School of Business Administration. Nadja completed their studies from 2006 until 2009.
This person is not in any teams
medac GmbH
We are a privately held, medium-sized global pharmaceutical and diagnostics company based in Germany. For more than 50 years we have been committed to high quality products, reliable supply and individual customer services. Today, over 2.000 medac employees worldwide are working together to supply more than 90 countries with our products. Since our foundation we have been specialising in the treatment of oncological, haematological, urological, and autoimmune diseases. Today, we are a leading specialist supplier in oncology and rheumatology. We combine the innovative power of a researching pharmaceutical company with the efficiency of a generics manufacturer and offer both therapeutics and diagnostics. Always putting the needs of patients and healthcare professionals first, we are committed to the refinement of established and the development of new products with additional benefits for patients in specific niche indications with high therapeutic needs.